It has been reported that more than 50% of human cancers carry somatic mutations of TP53 [5] and that mutant TP53 not only lose their tumor-suppressive functions [4, 8] but also acquire new transforming abilities to promote tumorigenesis, which are independent of wild-type TP53 [9–12]. The gene discussed is TP53; the disease is cancer.